Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Structure Therapeutics Inc. - American Depositary Shares (NQ:GPCR)

68.10 -1.45 (-2.08%)
Streaming Delayed Price Updated: 10:41 AM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Structure Therapeutics Inc. - American Depositary Shares

< Previous 1 2 3 4 5 Next >
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
The Case for Small-Cap Diversification: Why Investors are Looking Beyond Mega-Cap Tech
As 2025 draws to a close, the "Magnificent Seven" era of market dominance is facing its most significant challenge yet. While the first half of the year was characterized by a relentless surge in... 
Via MarketMinute
Topics Artificial Intelligence Economy
Why Did Structure Therapeutics Stock Surge Pre-Market Today? ↗
Via Stocktwits
News headline image
Novo Nordisk Breaks the Mold: Oral Obesity Breakthrough Sends Shares to New Heights as Pharma Landscape Shifts
BAGSVAERD, Denmark — In a landmark decision that has sent shockwaves through the global pharmaceutical industry, Novo Nordisk (NYSE:NVO) has secured U.S. Food and Drug Administration (FDA) approval for... 
Via MarketMinute
Topics Economy
News headline image
The Great Rotation: Small-Caps Seize the Spotlight as Mega-Cap Fatigue Sets In
As 2025 draws to a close, the financial landscape has undergone a seismic shift that few predicted at the start of the year. For the first time in over half a decade, the dominant narrative of "Big... 
Via MarketMinute
Topics Economy
News headline image
The Great Rotation: Small-Cap Growth Surges as Investors Ditch Defensive Safety for Post-Fed Gains
The financial markets are witnessing a historic "Great Rotation" this December, as the era of defensive posturing and mega-cap concentration appears to be giving way to a broad-based growth rally.... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
The Great Rotation: Small-Caps Break Out as Russell 2000 Hits Record Highs in Late 2025
NEW YORK — In a dramatic shift that has recalibrated the pulse of Wall Street, the Russell 2000 index has finally staged its long-awaited breakout, signaling a definitive end to the years-long... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Why Structure Therapeutics Stock Doubled and Then Some on Monday ↗
The company's investigational GLP-1 treatment performed admirably well in a phase 2b study. 
Via The Motley Fool
News headline image
What's going on in today's session ↗
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
Global Markets Brace for Fed Decision Amidst Divergent Policies and Geopolitical Crosscurrents
Global financial markets are treading a cautious path as December 9, 2025, unfolds, with investors keenly focused on the impending U.S. Federal Reserve's interest rate decision. The highly anticipated... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
Wondering what's happening in today's pre-market session? ↗
Wondering what's happening in Monday's pre-market session? Find an overview in this article. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
This Under-the-Radar Healthcare Stock Could Soar in 2026 ↗
We should know a lot more by year-end. 
Via The Motley Fool
Eli Lilly Stock Marks Worst Day In 25 Years As Weight-Loss Pill Data Disappoints: Analysts Divided But Retail Bets On Rebound ↗
Via Stocktwits
News headline image
Eli Lilly Shares Tumble as Oral Weight-Loss Hope Falls Short of Lofty Expectations
Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a significant downturn, plummeting over 10% in premarket trading and continuing to slide throughout the... 
Via MarketMinute
Topics Economy
News headline image
Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors ↗
Eli Lilly's obesity drug data misses targets, boosting shares of Novo Nordisk, Viking, Structure, and Terns amid promising trial updates. 
Via Benzinga
News headline image
Lilly Skids On A Shocking Obesity Setback. Novo, Viking, Structure Surge. ↗
An analyst called the unexpected flop a "once-in-a-blue-moon" occasion for Eli Lilly's dominant weight-loss franchise. 
Via Investor's Business Daily
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
Traders are paying attention to the gapping stocks in Thursday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
News headline image
uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Wall Street Sees Pfizer's Weight-Loss Pill Exit As A Win For 2 Smaller Biotech Firms: Retail Turns Bullish ↗
Investors are now considering the possibility of Pfizer acquiring either of these companies as it looks for external candidates. 
Via Stocktwits
News headline image
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today ↗
Pfizer bows, but is not entirely out of the GLP-1 race. 
Via The Motley Fool
News headline image
What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday? ↗
Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid obesity drug competition. 
Via Benzinga
News headline image
The State of Weight Loss Drugs ↗
Via The Motley Fool
News headline image
AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. ↗
This is the drugmaker's first foray into weight-loss drugs. And it's not focusing on GLP-1. 
Via Investor's Business Daily
News headline image
Why Structure Therapeutics Stock Was Stumbling This Week ↗
Via The Motley Fool
News headline image
AI Pharma: 2 Paths to AI-Powered Drug Investment
AI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
News headline image
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst ↗
JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights. 
Via Benzinga
News headline image
Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche ↗
Under the deal's terms, Hansoh Pharma receives $112 million up front and a potential $1.9 billion in milestone payments. 
Via Investor's Business Daily
News headline image
Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.